165 related articles for article (PubMed ID: 38030171)
21. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.
Rojewska E; Ciapała K; Piotrowska A; Makuch W; Mika J
Front Pharmacol; 2018; 9():724. PubMed ID: 30050435
[TBL] [Abstract][Full Text] [Related]
23. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
Réus GZ; Becker IRT; Scaini G; Petronilho F; Oses JP; Kaddurah-Daouk R; Ceretta LB; Zugno AI; Dal-Pizzol F; Quevedo J; Barichello T
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():55-63. PubMed ID: 29030243
[TBL] [Abstract][Full Text] [Related]
24. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
25. Etiological classification of depression based on the enzymes of tryptophan metabolism.
Fukuda K
BMC Psychiatry; 2014 Dec; 14():372. PubMed ID: 25540092
[TBL] [Abstract][Full Text] [Related]
26. Tryptophan metabolism and disposition in cancer biology and immunotherapy.
Badawy AA
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36286592
[TBL] [Abstract][Full Text] [Related]
27. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
Fatokun AA; Hunt NH; Ball HJ
Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
[TBL] [Abstract][Full Text] [Related]
28. Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat.
Wang J; Li X; He S; Hu L; Guo J; Huang X; Hu J; Qi Y; Chen B; Shang D; Wen Y
J Ethnopharmacol; 2018 Mar; 214():13-21. PubMed ID: 29217494
[TBL] [Abstract][Full Text] [Related]
29. Quantification of IDO1 enzyme activity in normal and malignant tissues.
Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
[TBL] [Abstract][Full Text] [Related]
30. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.
Liu JJ; Raynal S; Bailbé D; Gausseres B; Carbonne C; Autier V; Movassat J; Kergoat M; Portha B
Biochim Biophys Acta; 2015 May; 1852(5):980-91. PubMed ID: 25675848
[TBL] [Abstract][Full Text] [Related]
31. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Ciapała K; Mika J; Rojewska E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
[TBL] [Abstract][Full Text] [Related]
32. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
33. [Diagnoses and new therapeutic strategy focused on physiological alteration of tryptophan metabolism].
Mouri A; Hasegawa M; Kunisawa K; Saito K; Nabeshima T
Nihon Yakurigaku Zasshi; 2023 May; 158(3):233-237. PubMed ID: 36990795
[TBL] [Abstract][Full Text] [Related]
34. DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota.
Zhao LP; Wu J; Quan W; Zhou Y; Hong H; Niu GY; Li T; Huang SB; Qiao CM; Zhao WJ; Cui C; Shen YQ
Front Immunol; 2022; 13():1089200. PubMed ID: 36776388
[TBL] [Abstract][Full Text] [Related]
35. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
36. Kynurenine Monooxygenase Expression and Activity in Human Astrocytomas.
Vázquez Cervantes GI; Pineda B; Ramírez Ortega D; Salazar A; González Esquivel DF; Rembao D; Zavala Vega S; Gómez-Manzo S; Pérez de la Cruz G; Pérez de la Cruz V
Cells; 2021 Aug; 10(8):. PubMed ID: 34440798
[TBL] [Abstract][Full Text] [Related]
37. Extension of life span by down-regulation of enzymes catalyzing tryptophan conversion into kynurenine: Possible implications for mechanisms of aging.
Oxenkrug G; Navrotska V
Exp Biol Med (Maywood); 2023 Apr; 248(7):573-577. PubMed ID: 37300401
[TBL] [Abstract][Full Text] [Related]
38. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
39. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
40. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
